Pfizer’s Prevenar 13 gets CHMP positive opinion for prevention of vaccine-type pneumococcal pneumonia in adults

Pfizer announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that the indication for Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) be expanded to include the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults 18 years and older.

Category One, Showcase, status, Uncategorized, What's Hot